Evidence map›Paper›PMID 42787733›Full record

ArticleResults in chemistry2026

Structure-activity relationships of quinoidal derivatives against

Luana A Machado, Karol R Francisco, Renata G Almeida, Yujie Uli Sun, Mai Shingyoji, Alysh M Mercer, Irving G Lopez, Rafaela S Ferreira, Guilherme A M Jardim, Conor R Caffrey and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Results in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luana A MachadoInstitute of Exact Sciences, Department of Chemistry, Universidade Federal de Minas Gerais, CEP 31270-901, Belo Horizonte, MG, Brazil.
Karol R FranciscoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9255 Pharmacy Lane, MC0657, University of California San Diego, La Jolla, CA 92093, USA.
Renata G AlmeidaInstitute of Exact Sciences, Department of Chemistry, Universidade Federal de Minas Gerais, CEP 31270-901, Belo Horizonte, MG, Brazil.
Yujie Uli SunCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9255 Pharmacy Lane, MC0657, University of California San Diego, La Jolla, CA 92093, USA.
Mai ShingyojiCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9255 Pharmacy Lane, MC0657, University of California San Diego, La Jolla, CA 92093, USA.
Alysh M MercerCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9255 Pharmacy Lane, MC0657, University of California San Diego, La Jolla, CA 92093, USA.
Irving G LopezCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9255 Pharmacy Lane, MC0657, University of California San Diego, La Jolla, CA 92093, USA.
Rafaela S FerreiraDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil.
Guilherme A M JardimInstitute of Exact Sciences, Department of Chemistry, Universidade Federal de Minas Gerais, CEP 31270-901, Belo Horizonte, MG, Brazil.
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9255 Pharmacy Lane, MC0657, University of California San Diego, La Jolla, CA 92093, USA.
Eufrânio N da Silva JúniorInstitute of Exact Sciences, Department of Chemistry, Universidade Federal de Minas Gerais, CEP 31270-901, Belo Horizonte, MG, Brazil.

Funding

RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
The catalytic core of the proteasome as a drug target to treat Human African TrypanosomiasisR21AI171824 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2022 to 2023
$435k
NIAID NIH HHS R21 AI171824NIAID NIH HHS T32 AI007036
6 · The paper itself

Abstract

Quinoidal compounds are a well-established class of redox-active molecules with recognized biological activities, including cytotoxicity and antiparasitic effects. In the context of human African trypanosomiasis (HAT), the demand for novel therapeutic options has encouraged interest in repurposing and further characterizing known compounds. In this study, a set of previously described quinoidal derivatives was evaluated for

Indexed as

QuinoidalTrypanosoma bruceiTrypanosomiasis

Identifiers

PMID42787733
PMCPMC13603873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.